SCHEMBL4480247

SCHEMBL4480247

Cn1cnc(-c2cccc(NC(=O)Nc3cccc(F)c3)c2)c1-c1cc2c(N)ncnc2s1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 10/20 0.85
KDR P35968 10/20 0.63
FLT1 P17948 3/20 0.63
KIT P10721 4/20 0.51
BRAF P15056 3/20 0.42
ROCK2 O75116 1/20 0.41
LIMK1 P53667 1/20 0.41
IKBKB O14920 1/20 0.40
PDPK1 O15530 1/20 0.40
EGFR P00533 1/20 0.40
NTRK1 P04629 1/20 0.40
LCK P06239 1/20 0.40
FYN P06241 1/20 0.40
CDK1 P06493 1/20 0.40
LYN P07948 1/20 0.40
PIM1 P11309 1/20 0.40
MARK3 P27448 1/20 0.40
MAPK1 P28482 1/20 0.40
FLT3 P36888 1/20 0.40
MAPK9 P45984 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4796059 0.92 TEK (1.00) TEKKDRFLT1KITBRAF
SCHEMBL4467818 0.90 TEK (0.83) TEKKDRFLT1KITBRAF
SCHEMBL4471994 0.90 TEK (0.85) TEKKDRFLT1KITBRAF
SCHEMBL4464925 0.89 TEK (0.70) TEKKDRFLT1KITBRAF
SCHEMBL4802186 0.89 TEK (0.86) TEKKDRFLT1KITBRAF
SCHEMBL4798793 0.87 TEK (0.78) TEKKDRFLT1MAPK1MAP4K4
SCHEMBL4484707 0.87 TEK (0.83) TEKKDRFLT1KITBRAF
SCHEMBL4800594 0.86 TEK (1.00) TEKKDRFLT1KITBRAF
SCHEMBL4801489 0.85 TEK (0.83) TEKKDRFLT1BRAFLIMK1
SCHEMBL4796015 0.85 TEK (0.86) TEKKDRFLT1KITROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476677-B2 Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2 ASTRAZENECA AB (SE) 2009-01-13 US claimed
EP-1716155-B1 SUBSTITUTED THIENO- AND THIAZOLO[2,3-D]PYRIMIDINES AND [2,3-C]PYRIDINES AS INHIBITORS OF TIE2 ASTRAZENECA AB (SE) 2008-02-27 EP claimed
US-20070135455-A1 Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 ASTRA ZENECA AB (SE) 2007-06-14 US claimed
US-7476677-B2 Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2 ASTRAZENECA AB (SE) 2009-01-13 US disclosed
EP-1716155-B1 SUBSTITUTED THIENO- AND THIAZOLO[2,3-D]PYRIMIDINES AND [2,3-C]PYRIDINES AS INHIBITORS OF TIE2 ASTRAZENECA AB (SE) 2008-02-27 EP disclosed
US-20070135455-A1 Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 ASTRA ZENECA AB (SE) 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135455-A1 Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 TIE1, TEK, TEKT1 TEK 2/4885KDR 4/4885FLT1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.